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Abstract
Purpose Erythropoiesis-stimulating agents (ESAs) are often
used in treatment of patients with chemotherapy-induced ane-
mia. Many studies have demonstrated an improved hemoglo-
bin (Hb) response when ESA is combined with intravenous
iron supplementation and a higher effectiveness of intrave-
nous iron over traditional oral iron formulations. A new for-
mulation of oral sucrosomial iron featuring an increased bio-
availability compared to traditional oral formulations has re-
cently become available and could provide a valid alternative
to those by intravenous (IV) route. Our study evaluated the
performance of sucrosomial iron versus intravenous iron in
increasing hemoglobin in anemic cancer patients receiving
chemotherapy and darbepoetin alfa, as well as safety, need
of transfusion, and quality of life (QoL).
Materials and methods The present study considered a cohort
of 64 patients with chemotherapy-related anemia (Hb >8 g/
dL <10 g/dL) and no absolute or functional iron deficiency,
scheduled to receive chemotherapy and darbepoetin. All pa-
tients received darbepoetin alfa 500 mcg once every 3 weeks
and were randomly assigned to receive 8 weeks of IV ferric
gluconate 125mgweekly or oral sucrosomial iron 30mg daily.
The primary endpoint was to demonstrate the performance of
oral sucrosomial iron in improving Hb response, compared to
intravenous iron. The Hb response was defined as the Hb in-
crease ≥2 g/dL from baseline or the attainment Hb ≥ 12 g/dL.
Results There was no difference in the Hb response rate be-
tween the two treatment arms. Seventy one percent of patients
treated with IV iron achieved an erythropoietic response, com-
pared to 70% of patients treated with oral iron. By conven-
tional criteria, this difference is considered to be not statisti-
cally significant. There were also no differences in the propor-
tion of patients requiring red blood cell transfusions and
changes in QoL. Sucrosomial oral iron was better tolerated.
Conclusion In cancer patients with chemotherapy-related
anemia receiving darbepoetin alfa, sucrosomial oral iron pro-
vides similar increase in Hb levels and Hb response, with
higher tolerability without the risks or side effects of IV iron.
Keywords Chemotherapy-related anemia . Oral iron . IV
iron . Hb response . Sucrosomial iron
Introduction
Cancer-associated anemia is a common condition reflecting a
pathologic deficiency in the amount of oxygen-carrying
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hemoglobin in red blood cells (RBC). It is estimated that the
prevalence of anemia in cancer patients before starting cancer
treatment is approximately 40% (due to the disease itself,
blood loss, hemolysis, bone marrow infiltration, etc.), with
incidence rising to over 80% as a consequence of chemother-
apy (myelosuppression by chemo- and radiotherapy, toxicity
of anti-targeted therapies) [1, 2]. Furthermore, cancer patients
may present an absolute iron deficiency (AID) due to bleeding
or poor iron diet or a functional iron deficiency (FID) leading
to anemia of chronic disease (ACD), likely caused by a chron-
ic state of inflammation [3–5]. Together, these factors contrib-
ute to low hemoglobin (Hb) levels and consequently affect the
patient’s physical performance and QoL, disease response,
and disease morbidity [5–8].
In accordance with the recommendations by the guidelines
of major medical societies [9–12], current treatment for
chemotherapy-associated anemia often relies on the use of
erythropoietic-stimulating agents (ESAs) to reduce need of
transfusion, increase Hb levels, and relieve anemia-related
symptoms; yet response rates to ESA alone have been subop-
timal, yielding a positive response in only 40% of patients [4,
5]. Several major studies [4, 13–15] have demonstrated, how-
ever, that better responses in terms of increased Hb response
and decreased ESA treatment time are obtained when ESA is
given in combination with iron supplementation, which seems
to contribute to the correction of erythropoiesis and to com-
pensation in case of a concomitant iron deficiency [13, 16].
To date, iron supplementation in combination with ESAs
has demonstrated to be more effective through intravenous
infusion (IV), compared to conventional oral iron supplemen-
tation [13, 17], which would be expected in light of the recent
findings on hepcidin and the limited gastrointestinal absorp-
tion of iron. According to the study by Auerbach et al. [13] on
cancer patients with anemia caused by iron deficiency, the
percentage of response to erythropoietin (EPO) was increased
by both IV and oral iron supplementation (IV 68% vs oral
36%). The study byHenry et al. on cancer patients undergoing
chemotherapy evaluated the effect of IV and oral iron sulfate
on patients with and without iron deficiency and found the
efficacy of conventional oral supplementation to be markedly
lower than IV iron [14]. In the attempt of summarizing find-
ings of published studies, a meta-analysis by Pedrazzoli et al.
confirmed the efficacy of IV iron supplementation, in anemic
cancer patients, in yielding best hematopoietic response with a
quicker time of response and a reduction in the number of
blood transfusions [4]. Further insight provided by the review
byKarlsson on over six clinical trials evaluating ESAs plus IV
iron in cancer patients confirmed findings of previous studies,
where erythropoietic response in anemic patients receiving
ESA is augmented as result of IV iron supplementation [18].
Finally, it appears that hematopoietic response would be relat-
ed to the dose of IV iron independent of the patients’ iron
status [17, 19].
However, during the same years of these studies, the Italian
Medicines Agency (AIFA) in agreement with the European
Medicines Agency (EMA) released a recommendation warn-
ing on the risk of potentially fatal hyper-sensitization reactions
caused by IV iron, which brought new focus onto other more
effective and safer ways of iron supplementation [20, 21].
Recently, a new oral formulation of ferric pyrophosphate
(Sideral® Forte), featuring high bioavailability (approximate-
ly threefold that of the gold standard, ferrous sulfate) and a
good safety profile, has become available in most European
countries [22, 23]. The distinguishing feature of this formula-
tion has been assessed in a number of studies [22, 24–27] and
has shown to be devoid of common side effects of conven-
tional oral iron supplementation such as stomach pain, nausea,
constipation, discoloration of the mucous, and feces.
Moreover, its safety has been recently confirmed in a recent
randomized study on a cohort of non-anemic pregnant women
[26].
In the past 5 years, a number of studies have been focusing
on patients with FID or AID; however, they do not consider
those patients with cancer-related anemia, who have neither
FID nor AID, but who still might benefit from iron supple-
mentation. A previous study on patients with chemotherapy-
related anemia and no iron deficiency has evaluated whether
this patient population responded better to darbepoetin (DA)
or ESA treatment with IV iron supplementation and found that
iron supplementation did significantly reduce treatment fail-
ures with DAwithout causing additional toxicity [15]. Hence,
our interest focused on oral sucrosomial iron supplementation
on this same type of population.
The primary aim of the present study was to perform a
retrospective evaluation on the comparability in efficacy of
oral sucrosomial iron supplementation in anemic cancer pa-
tients featuring neither FID nor AID and receiving
darbepoetin, a relatively long-acting ESA, in comparison with
IV iron supplementation in the setting of cancer supportive
treatments implemented at our hospitals.
Secondary objectives were safety, effect on number of
RBC units transfused, and QoL.
Materials and methods
Study design and patient population
This was a retrospective pilot study, performed between
May 2012 and Nov 2013, involving two Oncology
Departments in Southern Italy. The study considered 64 cancer
patients with cancer-related anemia scheduled for chemother-
apy and treatment with darbepoetin and iron supplementation.
Inclusion criteria were chemotherapy-related anemia, age
≥18 years, diagnosis of major solid tumors (breast cancer and
non-small cell lung cancer), 8 < Hb <10 g/dL, serum ferritin
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≥100 ng/mL, or transferrin saturation ≥15%, Eastern
Cooperative Oncology Group Performance Score (ECOG
PS) 0–2, life expectancy ≥6 months, at least 8 weeks of resid-
ual chemotherapy independent of the iron status and adequate
liver and kidney function.
Exclusion criteria were AID (ferritin below the lower
limit of the normal range or transferrin saturation <10%),
FID (transferrin saturation <20% and ferritin >100 μg/mL)
[15] or iron overload (transferrin saturation ≥45% and fer-
ritin ≥800 ng/mL) upon enrolment, primary hematologic
disorder causing moderate to severe anemia, bone marrow
diseases, known bone marrow involvement, comorbid car-
diovascular disease incompatible with ESA treatment, ac-
tive infections, and ESA treatment or blood transfusions
within 8 weeks.
The total observation time was 8 weeks of treatment plus
4 weeks of follow-up during which Hb and biochemical iron
levels were also monitored during weekly checkup.
Treatment
Patients receiving treatment with darbepoetin alfa (500 mcg)
every 3 weeks (as by treatment schedule previously
established by the oncologist) were administered iron supple-
mentation, either as IV ferric gluconate or as oral sucrosomial
iron (Sideral® Forte, PharmaNutra SpA, Pisa, Italy), as
established by the oncologist for a total of 8 weeks.
Sucrosomial iron is a patented formulation made of ferric
pyrophosphate, lecithin, and sucrester. Patients receiving IV
iron were administered iron by dosages of 125 mg/week of
ferric gluconate (Ferlixit, Sanofi), corresponding to two vials
diluted in 250 mL of sodium chloride 0.9% in 60 min admin-
istered in the out-patient clinic of the oncology center (with
emergency personnel, as required by AIFA and EMA recom-
mendation warnings on patient safety) [20, 21], whereas pa-
tients receiving oral iron were given a dosage of 30 mg/day of
sucrosomial iron (Sideral® Forte), corresponding to one cap-
sule/day.
Adjustments to ESA doses were made, as appropriate,
based on patient response and clinical status and in agreement
with product information sheet [28]: when levels of Hb were
>12 g/dL, the dose of ESAwas reduced by 25–50%; when Hb
were >13 g/dL, treatment with darbepoetin was temporarily
interrupted and resumed; in case of a drop of Hb values below
12 g/dL, treatment was resumed with a 25% ESA dose reduc-
tion. In the case the Hb increase was >2 g/dL in 4 weeks, dose
was reduced 25–50%.
Patients receiving IVor oral iron had consented to supple-
mentation based on the oncologist’s treatment suggestions and
recommendations, as they had previously did for all other
treatments. The study was conducted in line with principles
outlined in the Declaration of Helsinki.
Endpoints and measurements
The endpoints measured included increase in Hb levels after
administration of oral sucrosomial iron, compared to Hb
levels after administration of IV ferric gluconate. Hb response
was defined as Hb increase >2 g/dL from baseline or achiev-
ing Hb ≥12 g/dL.
Secondary endpoints included parameters referring to safe-
ty profile evaluated as occurrence of adverse events (AEs) or
serious adverse events (SAEs), need for transfusions (yes/no),
patient response time and improvement in QoL scores.
QoL was measured by the use of standard questionnaires
validated for evaluating QoL in chronic illness, namely the
Functional Assessment of Cancer Therapy for anemia in can-
cer patients (FACT-An version 4) and the Linear Analog Self
Assessment (LASA) for cancer patients during chemotherapy
[29, 30]. Both questionnaires are patient-reported outcome
tools covering functional, physical, and emotional areas, and
ask patients to provide answer based on a Likert scale.
Questionnaires were administered to all patients at baseline
and after 8 weeks.
Patient compliance to iron supplementation was monitored
during checkup by the oncologist through the patient’s reports
and/or by patient’s request for refill of the empty blisters.
Statistical methods
Variables were expressed as mean ± standard deviation or
count and proportion, depending on their distributions.
Accordingly, comparisons were performed with unpaired
samples t test or chi-squared test with continuity correction.
Response curves were compared with two-way ANOVA.
Computations were executed in SPSS Statistics (IBM), ver-
sion 21. A value of p < 0.05 was considered statistically
significant.
Results
The total patient population considered for the analyses
consisted in 64 patients (Table 1) either treated with IV iron
or oral iron.
The mean baseline level of measured Hb was 9.4 g/dL in
the darbepoetin + sucrosomial iron group and 9.2 g/dL in the
darbepoetin + IV iron group. At least 30% of patients in each
treatment group were treated with platinum-based chemother-
apy, a therapy that heavily influences treatment-induced ane-
mia compared to other types of chemotherapy.
Of all patients recruited and undergoing treatment, there




Efficacy analyses have shown that response to treatment (in-
crease in Hb >2 g/dL from baseline or achieving Hb ≥12 g/dL)
was achieved by 71% of patients treated with IV iron and by
70% of patients supplemented with oral sucrosomial iron,
with no statistically significant differences (Fig. 1). Chi-
squared was equal to 0.014 with 1 degree of freedom. The
two-tailed p value was equal to 0.9060.
These results support the comparability of oral sucrosomial
iron supplementation versus intravenous iron in patients with
chemotherapy-related anemia.
Safety
No differences were found between the two treatment groups
as to patients requiring RBC transfusion. As to adverse or
serious adverse events related to iron supplementation, these
were found in 6% of patients in the IV group (adverse reaction
due to IV infusion) while none were found in the group sup-
plemented with oral iron, as shown in Table 2.
Overall, 43.7% of patients reported adverse events.
4.7% were serious adverse events such as gastrointestinal
toxicity (abdominal pain, diarrhea) related to chemothera-
py treatment (one patient in Sideral group), infusion reac-
tion to IV iron (two patients in IV iron group), and two
thromboembolic events (one per study group) most likely
caused by treatment with darbepoetin. One fatal event per
treatment group was reported but was not related to iron
therapy.
Time to response
Statistical analysis of the time tomaximum response showed a
comparable profile between the two treatments (p = 0.902) in
terms of Hb increase, as reported in Fig. 2.
RBC transfusions
The number of transfusions needed was equal in the two
groups (one patient in each group, 3%).
QoL
Results from the questionnaires in both patient groups showed
comparable changes in quality of life parameters and compat-
ible with a gain in Hb levels. In particular, items most specif-
ically linked to benefits from iron (fatigue/tiredness, general
weakness, shortness of breath, feeling energetic, function, be-
ing too tired to eat and motivation to perform daily chores)
confirmed an improved QoL perception in both groups
(Supplemental material).
Discussion
Despite it is acknowledged that the use of iron supple-
mentation in addition to ESA treatment significantly im-
proves the hematopoietic response to ESAs in dialysis
patients with chronic anemia, the use of oral supplemen-
tation in cancer patients is still suboptimal [4]. In chronic
illnesses, the establishment of a permanent inflammatory
status leads to the production of cytokines such as IL-1α
and TNF-α, that prevents EPO production from kidneys,
and the pro-inflammatory cytokine IL-6 that acts on the
liver and induces the production of hepcidin. This peptide
plays a key role in iron homeostasis, inhibiting intestinal
iron absorption and impeding the release of iron from the
stores [2, 31–33]. The presence of inflammation and, thus,
Fig. 1 Hb response in the two treatment groups







n = 33 n = 31
Sex
Female, n (%) 13 (40) 12 (39) 1
Males, n (%) 20 (60) 19 (61) 1
Type of cancer
Breast, n (%) 10 (30) 10 (32) 1
Lung, n (%) 23 (70) 21 (68) 1
Type of chemotherapy
Chemo platinum, n (%) 10 (30) 12 (38) 1
ECOG Performance status
0, n (%) 22 (66) 19 (62) 1
1, n (%) 10 (30) 10 (32) 1
2, n (%) 1 (3) 2 (6) 1
Iron status
Baseline Hb g/dL (mean) 9.4 9.2 0.932
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high levels of hepcidin may limit the availability of cir-
culating iron needed by RBC progenitors, hindering a
correct erythropoiesis and eventually leading to the devel-
opment of anemia of chronic disease [5, 34]. Thus, cancer
patients, who present high or normal ferritin level, but
also low circulating iron levels, may benefit from iron
supplementation.
The issue of chemotherapy-induced anemia and low Hb
levels in cancer patients is associated with poor physical per-
formance status and disease-related fatigue.
Until recently (with the understanding of the mechanisms
underlying FID), anemia has been largely underestimated. In
2004, an ECAM survey documented that anemia was left
untreated in over 61% of cancer patients, being partly ex-
plained by a broad misconception around anemia in cancer
patients (who often feature normal serum ferritin levels) and
around the poor tolerability towards traditionally used iron
formulations [3, 4], which is no longer applicable to newer
formulations.
As a result of a growing number of studies on iron supple-
mentation with ESAs [5], recent guidelines on the use of these
agents [11] stress the importance of monitoring iron levels in
patients and providing adequate supplementation in order for
the patient to gain more benefit from ESA treatment, to im-
prove Hb response, and to restore functional iron levels.
The present study specifically addressed the comparability
of oral sucrosomial iron to ferric gluconate, a broadly used IV
formulation, which has already been evaluated in a number of
previous studies [14, 15] in combination with the long-acting
ESA, darbepoetin.
Sucrosomial iron (Sideral®) is a preparation of ferric
pyrophosphate conveyed and protected into a phospho-
lipids and sucrester matrix. Differently from other formu-
lations, it features low non-toxic dose of sucresters, which
protect iron from the acid environment of the stomach and
increase its permeability, allowing higher absorption of
exogenous iron [22, 23]. In addition, it is characterized
by an alternative route of absorption and delivery, which
allows the reduction of side effects and the prevention of
iron instability in the gastrointestinal tract. Preliminary
studies seem to suggest that sucrosomial iron might also
exert a down-regulatory effect on hepcidin in chronic in-
flammation [35]. Taken together, these characteristics pro-
vide obvious advantages over other oral formulations,
which have resulted less efficacious, compared to IV iron
supplementation, in supporting Hb response in cancer pa-
tients receiving treatment with ESA.
Overall results showed comparable efficacy of sucrosomial
iron to that of ferric gluconate in anemic patients not FID and
not AID. Both IV and oral sucrosomial iron gave a good re-
sponse rate (70 and 71%, respectively), with a maximum re-
sponse rate achieved among patients with Hb >9 g/dL and a
significantly lower response rate among patients with Hb
≤9 g/dL. This could be explained by the delicate balance in-
volved in iron homeostasis.
In reference to the time to response, oral sucrosomial
iron showed a comparable result to IV iron that was main-
tained for the rest of the monitoring period. Time to Hb
response is an important parameter to consider in cancer
patients undergoing treatment with ESA. As it is well dem-
onstrated, ESAs are associated to severe AEs (venous
thromboembolism, tumor progression, stroke, and recur-
rence of disease) and overall mortality [36–38]. In fact,
recent guidelines such as ASCO and NCCN [10, 11]
Table 2 Adverse events (AEs)
and serious AEs reported in pa-
tients by treatment groups
Darbepoetin +
sucrosomial iron n = 33
Darbepoetin +
IV iron n = 31
p
Patients with adverse events, n (%) 13 (39) 15 (48) 0.636
Patients with serious adverse events, n (%) 2 (6) 1 (3) 1
Gastrointestinal toxicity EPS-related, n (%) 1 (3) 0 1
Infusion reaction to IV iron, n (%) 0 2 (6) 1
Thromboembolic events, n (%) 1 (3) 1 (3) 1
Fatal events
Overall, n (%) 1 (3) 1 (3) 1
Treatment related, n (%) 0 0 1
Fig. 2 Comparison of time to response (in weeks) between the two
treatment groups
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recommend that ESA should be administered for the least
amount of time and at the minimum dose possible to elicit
sufficient RBC levels to limit the need to turn to blood
transfusions and to improve QoL. A quicker response,
thus, is desirable.
An observational study by Giordano et al. [39] on
sucrosomial iron in patients with sideropenic anemia con-
firmed the reduction of the typical side effects of a conven-
tional martial treatment, determining at the same time an
improvement of the patient’s anemic condition in terms of
serum iron, Hb, and ferritin [24, 25, 39]. Another study by
Pisani et al. [27] in patients with chronic kidney disease
demonstrated the non-inferiority of the oral sucrosomial
iron compared to IV iron therapy in terms of increase in
Hb levels.
From the QoL perspective, iron supplementations rep-
resent a remarkable aid in dealing with cancer-related fa-
tigue and preventing other related symptoms such as im-
paired cognitive function, headache, dizziness, chest pain,
shortness of breath, nausea, and depression [6, 29, 30]. A
recent German study on the overall QoL, as measured by
the FACT-An total scores, showed a median anemia-
related score improvement for patients receiving IV iron
or ESA associated with IV iron after 12 weeks of treatment.
The difference reached the level of clinical relevance (≥7
points) for patients receiving ESA associated with IV iron
(106.5 to 117.5 points) [40]. Likewise, the same tool,
which is specifically validated for assessment in anemic
cancer patients, was used also for our cohort.
All patients (both in the group of oral and IV supple-
mentation) equally reported perceived benefits at 8 weeks.
Parameters, such as fatigue/tiredness, general weakness,
shortness of breath, feeling energetic, function, being too
tired to eat, and motivation to perform daily chores, were
all improved as expected with a gain in Hb level. Despite
the small study population, such improvement quality of
life represents a great achievement in patients with non-
curable cancer, as it allows individuals to maintain func-
tion in daily life activities (in many cases these may also
extend to family duties, work, etc.). The lack of differences
in responses between the two groups is encouraging and
confirms a comparable effect to IV as to benefits on QoL.
Moreover, comparing the safety profile and efficacy of iron
supplementations, the option of an effective oral supple-
mentation in capsules may be less burdensome on the pa-
tient‘s logistics and further improve the patient’s QoL, as
compared to a more invasive IV iron infusion at the out-
patient clinic.
From a safety point of view, the advantages of oral
sucrosomial iron supplementation are even more relevant in
consideration of the recent safety warning [20, 21] on the
potentially fatal effects of IV iron infusions, making an oral
iron supplementation even more desirable.
From the prospective of patient management and costs
involved for the healthcare system, IV infusion has also
specific procedure requirements. Firstly, each IV session
requires that the hematology unit reserve a transfusion
station/seat for the time required for the procedure, mon-
itor the patient (approximately 3 h), and dedicate person-
nel on shift during operation, which occupies resources
that could be dedicated to other duties. Considering that
the need for IV iron supplementation is evaluated on a
patient-to-patient basis, the frequency of supplementation
might imply up to three infusions per week. Secondly,
IV iron can only be performed in authorized centers
equipped with emergency and intensive care profes-
sionals, which excludes many patient reference centers
at local level, thus, potentially discouraging physicians
and patients from supplementation.
Overall, performance of oral sucrosomial iron was compa-
rable to that of IV iron and produced comparable advantages
for patients in both functional and emotional wellbeing, and
Hb levels, suggesting a potential benefit also in reducing the
need for transfusions for such patients and the morbidity of the
malignancy.
Limits
The study was performed on a small sample size and was
based on data from only two oncology centers, which limits
the generalizability of the results.
Despite presenting an important bias given by the choice of
treating both patients with iron deficit and true-replete patients
with Hb >9 g/dL, the study provided important findings on the
efficacy and safety of oral sucrosomial iron in patients treated
with ESA.
Taken together, our study represents a small contribution in
addressing the objectives set by ASCO (and other societies
thereafter) since 2007, requesting further research to be done
on iron supplementation in cancer patients treated with ESA
and on iron formulation.
Conclusions
Oral sucrosomial iron supplementation in association to
darbepoetin has shown comparable efficacy to IV ferric glu-
conate associated to ESA in the treatment of chemotherapy-
related anemia. Moreover, in consideration of the recent safety
warning on IV iron and its potential serious adverse events,
oral sucrosomial iron represents a valid alternative to the more
invasive IV iron supplementation.
The sophisticated sucrosomial technology allows a higher
absorption and bioavailability of iron with minimal side ef-
fects on the gastrointestinal tract.
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